Liposome-Encapsulated Doxorubicin Citrate and Carboplatin in Treating Patients With Advanced or Metastatic Recurrent Endometrial Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01100359
Recruitment Status : Unknown
Verified February 2011 by National Cancer Institute (NCI).
Recruitment status was:  Recruiting
First Posted : April 8, 2010
Last Update Posted : August 7, 2013
Information provided by:
National Cancer Institute (NCI)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as liposome-encapsulated doxorubicin citrate and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This phase II trial is studying how well liposome-encapsulated doxorubicin citrate given together with carboplatin works in treating patients with advanced or metastatic recurrent endometrial cancer.

Condition or disease Intervention/treatment Phase
Endometrial Cancer Drug: carboplatin Drug: liposome-encapsulated doxorubicin citrate Other: laboratory biomarker analysis Procedure: quality-of-life assessment Phase 2

Detailed Description:



  • To assess activity of the combination of liposome-encapsulated doxorubicin citrate and carboplatin in patients with primary advanced or metastatic recurrent carcinoma of the endometrium.


  • To assess the toxicity and feasibility of this regimen in these patients.
  • To determine the progression-free survival and overall survival of these patients.

OUTLINE: This is a multicenter study.

Patients receive liposome-encapsulated doxorubicin citrate IV over 1 hour followed by carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6-9 courses in the absence of disease progression or unacceptable toxicity.

Tissue array and immunohistochemistry analysis are conducted on paraffin-embedded tumor blocks of the primarily operated tissue of all patients for different markers (e.g., progesterone-/estrogen receptor, HER2-receptor, soluble L1-molecule, Topo 2a) to examine tumor characteristics.

Quality of life is assessed at baseline, during study treatment, at completion of study treatment, and then at 1 year after completion of study treatment.

After completion of study therapy, patients are followed up every 3 months for 1 year.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Multicenter Trial of the Austrian AGO With the Combination of Liposomal Doxorubicin (Myocet®) and Carboplatin in Primary Advanced or Metastatic and Recurrent Endometrial Cancer
Study Start Date : November 2007
Estimated Primary Completion Date : October 2010

Primary Outcome Measures :
  1. Response rate

Secondary Outcome Measures :
  1. Duration of progression-free survival
  2. Overall survival
  3. Safety
  4. Feasibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of endometrial carcinoma, including any of the following cellular types:

    • Mixed Mullerian carcinoma
    • Serous carcinoma
    • Clear cell carcinoma
  • Primary advanced (FIGO stage III or stage IV) or metastatic recurrent disease
  • Disease not curable by surgery
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm with x-ray, physical exam, or non-spiral CT scan OR ≥ 10 mm with spiral CT scan or MRI
  • No known cerebral metastases


  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • Platelet count ≥ 100,000/mm^3
  • ANC ≥ 1,500/mm^3
  • Hemoglobin ≥ 10 g/dL
  • Creatinine ≤ 1.25 times upper limit of normal (ULN)
  • Bilirubin ≤ 1.25 times ULN
  • AST/ALT < 3 times ULN
  • Glomerular filtration rate ≥ 50 mL/min
  • LVEF ≥ 50% by ECHO
  • Fertile patients must use effective contraception
  • No myocardial infarction within the past 6 months
  • No NYHA class II-IV congestive heart failure
  • No third degree or complete heart block unless a pacemaker is in place
  • No other malignancy within the past 5 years
  • No concomitant medical illness (e.g., uncontrolled infection, uncontrolled angina, or other relevant illness) that makes the prescribed treatments within this study unfeasible
  • No known hypersensitivity to study drugs
  • No psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and follow-up schedule


  • No prior chemotherapy for disease recurrence
  • At least 12 months since prior adjuvant therapy containing anthracyclines with cumulative doses not exceeding the following:

    • Epirubicin 600 mg/m²
    • Doxorubicin 300 mg/m²
  • At least 6 months since prior adjuvant therapy containing platinum
  • At least 4 weeks since completion of radiotherapy involving the whole pelvis
  • No concurrent radiotherapy or planned radiotherapy after study
  • No concurrent endocrine, immunological, or other anticancer therapy
  • No concurrent participation in another investigational drug study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01100359

Innsbruck Universitaetsklinik Recruiting
Innsbruck, Austria, A-6020
Contact: Contact Person    43-512-504-23050   
Sponsors and Collaborators
Medical University Innsbruck
Study Chair: Christian Marth, MD, PhD Medical University Innsbruck Identifier: NCT01100359     History of Changes
Other Study ID Numbers: MUI-AGO-15
CDR0000669712 ( Registry Identifier: PDQ (Physician Data Query) )
First Posted: April 8, 2010    Key Record Dates
Last Update Posted: August 7, 2013
Last Verified: February 2011

Keywords provided by National Cancer Institute (NCI):
endometrial clear cell carcinoma
recurrent endometrial carcinoma
stage IIIA endometrial carcinoma
stage IIIB endometrial carcinoma
stage IIIC endometrial carcinoma
stage IVA endometrial carcinoma
stage IVB endometrial carcinoma

Additional relevant MeSH terms:
Endometrial Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Uterine Diseases
Genital Diseases, Female
Liposomal doxorubicin
Citric Acid
Antineoplastic Agents
Antibiotics, Antineoplastic
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Calcium Chelating Agents
Chelating Agents
Sequestering Agents